GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma - 30/01/14
Doi : 10.1016/j.jaci.2013.08.024
Louise Hosking, BSc a 
, Eugene Bleecker, MD b, Soumitra Ghosh, MD, PhD c, Astrid Yeo, PhD a, Loretta Jacques, PhD d, Michael Mosteller, PhD e, Deborah Meyers, PhD b
, Eugene Bleecker, MD b, Soumitra Ghosh, MD, PhD c, Astrid Yeo, PhD a, Loretta Jacques, PhD d, Michael Mosteller, PhD e, Deborah Meyers, PhD b a Department of Projects Clinical Platforms and Sciences, GlaxoSmithKline Research and Development, Stevenage, United Kingdom
b Center for Human Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC
c Department of Projects Clinical Platforms and Sciences, GlaxoSmithKline Research and Development, Upper Merion, Philadelphia, Pa
d Medicines Development Centre Global Clinical, GlaxoSmithKline Research and Development, Stockley Park, United Kingdom
e Department of Projects Clinical Platforms and Sciences, GlaxoSmithKline Research and Development, Research Triangle Park, NC
| The clinical studies described in this article were funded by GlaxoSmithKline. E. Bleecker (grant no. U01 HL65899) and D. Meyers (grant no. RC2 HL101487) were funded by grants from the National Institutes of Health. |
|
| Disclosure of potential conflict of interest: L. Hosking, S. Ghosh, A. Yeo, L. Jacques, and M. Mosteller are employees of and hold stock in GlaxoSmithKline. E. Bleecker has received grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute, Aerovance, AstraZeneca, Boehringer-Ingelheim-Pfizer, Centocor, Cephalon, Ception, Forest, Genentech, GlaxoSmithKline, MedImmune, Novartis, and Sanofi-Aventis and has consultant arrangements with GlaxoSmithKline, Boehringer-Ingelheim-Pfizer, Forest, Novartis, Regeneron, and Sanofi-Aventis. D. Meyers has been supported by one or more grants from the NIH. The rest of the authors are employed by and own stock/stock options in GlaxoSmithKline. |
© 2013
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 133 - N° 2
P. 587-589 - février 2014 Retour au numéro
Article précédent
- Specific IgE reactivity to Tri a 36 in children with wheat food allergy
- Alexandra Baar, Sandra Pahr, Claudia Constantin, Stavroula Giavi, Alkisti Manoussaki, Nikolaos G. Papadopoulos, Christof Ebner, Adriano Mari, Susanne Vrtala, Rudolf Valenta
- New childhood and adult reference intervals for total IgE
- Thomas B. Martins, Michael E. Bandhauer, Ashley M. Bunker, William L. Roberts, Harry R. Hill
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?